Study finds distinct immune response in COVID-19 and sepsis patients

Medical News: COVID-19 and sepsis are two medical conditions that share some similarities, especially in how they can lead to organ failure and death in severe cases. Both diseases cause an exaggerated immune response, often leading to life-threatening complications like respiratory failure and multi-organ dysfunction. However, a recent study led by researchers from institutions across Europe, including Radboud University Medical Center in the Netherlands and Hacettepe University Cancer Institute in Turkey, has revealed key differences in how the body regulates certain immune responses in these two conditions. This Medical News report explores the findings, detailing how the regulation of specific immune markers can differ between COVID-19 and sepsis patients.


Study finds distinct immune response in COVID-19 and sepsis patients

What the Study Looked At
The study focused on how the body regulates two important immune system markers: the soluble receptors of Tumor Necrosis Factor (TNF) and Interleukin-1 (IL-1). These molecules play a critical role in controlling inflammation, a key feature of both COVID-19 and sepsis. TNF and IL-1 are pro-inflammatory cytokines, meaning they promote inflammation, which is a necessary part of the body's response to infection. However, when these cytokines are not properly regulated, they can lead to excessive inflammation, which can cause tissue damage and organ failure.
 
The researchers examined how the soluble forms of TNF and IL-1 receptors behave in the plasma of patients with COVID-19, severe bacterial infections, and sepsis.
 
Key Study Findings
The research team discovered significant differences in the behavior of these receptors between COVID-19 and sepsis patients. In COVID-19 patients, levels of soluble IL-1 receptor type I (sIL-1R1) were much higher compared to healthy individuals. This increase was particularly noticeable in patients who were admitted to the Intensive Care Unit (ICU), indicating that higher levels of sIL-1R1 might be linked to more severe disease. On the other hand, sepsis patients showed decreased levels of sIL-1R1 but had elevated levels of another receptor, sIL-1R2, as well as TNF receptors sTNFR1 and sTNFR2.
 
The researchers used several methods to compare these receptors, including measuring their levels in the blood and analyzing their gene expression in immune cells. They found that while both COVID-19 and sepsis patients had elevated levels of TNF receptors, the pattern of IL-1 receptor regulation was different. In COVID-19, the body seemed to produce more of the sIL-1R1 receptor, potentially as a way to counterbalance the harmful effects of inflammation. However, in sepsis, the body produced more sIL-1R2, which acts as a "decoy" receptor, soaking up excess IL-1 and potentially preventing further inflammation.
 
Differences in Immune Response Between COVID-19 and Sepsis
One of the most important takeaways from this study is that the immune response in COVID-19 and sepsis, while similar in some ways, is also fundamentally different. Both dis eases are characterized by a hyperactive immune response that can lead to severe illness, but the way the body attempts to regulate this response differs.
 
In COVID-19 patients, the increase in sIL-1R1 may be the body’s attempt to mitigate the effects of IL-1, which is known to drive inflammation. This suggests that IL-1 signaling might be more important in the progression of COVID-19 than in sepsis. In contrast, the elevated levels of sIL-1R2 in sepsis patients point to a different mechanism at play, one that may involve dampening the effects of IL-1 more directly.
 
The Role of TNF in Both Conditions
TNF is another key player in the body’s immune response. It has been shown to play a crucial role in controlling infections, but it can also contribute to harmful inflammation when not properly regulated. In both COVID-19 and sepsis, the study found elevated levels of the soluble TNF receptors, sTNFR1 and sTNFR2. These receptors help regulate TNF activity by either inhibiting it or stabilizing TNF, depending on the circumstances. The researchers found that the levels of these receptors were similarly elevated in both COVID-19 and sepsis patients, suggesting that TNF regulation is a common feature of both conditions.
 
Interestingly, while the TNF receptors were elevated in both diseases, there was no significant difference in the levels of these receptors between ICU and non-ICU COVID-19 patients. This indicates that TNF regulation might not be as closely tied to disease severity in COVID-19 as IL-1 regulation is.
 
Gene Expression Differences
The study also delved into the genetic regulation of these immune markers, examining how the genes that encode for IL-1 and TNF receptors are expressed in different types of immune cells. They found that in COVID-19 patients, the genes for IL-1 receptors were more highly expressed in monocytes, a type of immune cell, particularly in those with severe disease. This suggests that monocytes play a key role in the immune response to COVID-19. In contrast, the expression of TNF receptor genes was less clearly linked to disease severity, indicating that other factors might be involved in regulating TNF activity in these patients.
 
In sepsis patients, the researchers observed a significant increase in the expression of IL-1R2 in monocytes, further supporting the idea that this receptor plays a key role in regulating the immune response in sepsis. The transcription of TNF receptors in sepsis was not as markedly altered, but the increased number of monocytes likely contributed to the elevated levels of soluble TNF receptors observed in the blood.
 
Conclusions
This study offers new insights into the differences in immune regulation between COVID-19 and sepsis. While both diseases involve an overactive immune response, the way the body attempts to regulate this response is distinct. In COVID-19, the increase in sIL-1R1 suggests that IL-1 signaling plays a more prominent role, particularly in severe cases. In contrast, sepsis patients show a stronger reliance on sIL-1R2, indicating a different approach to controlling inflammation. Both diseases, however, involve elevated levels of soluble TNF receptors, suggesting that TNF regulation is a common factor.
 
These findings could have important implications for the treatment of both COVID-19 and sepsis. Therapies that target IL-1 or TNF signaling might need to be tailored to the specific disease, as the underlying mechanisms of immune regulation appear to differ. For example, treatments that block IL-1 signaling, such as the use of IL-1 receptor antagonists, might be more effective in COVID-19 patients, while therapies that target TNF might be beneficial in both diseases.
 
The study findings were published in the peer-reviewed Journal of Infection.
https://www.sciencedirect.com/science/article/pii/S0163445324002342

For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/study-reveals-key-differences-in-blood-clotting-responses-between-covid-19-and-non-covid-sepsis-patients
 
https://www.thailandmedical.news/news/phytochemicals-as-potential-saviors-against-covid-19-associated-sepsis
 
https://www.thailandmedical.news/articles/sepsis